We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Protein Biomarker Improves Early Diagnosis of Alzheimer's Disease

By LabMedica International staff writers
Posted on 09 May 2011
The level of specific biomarkers in the plasma and cerebrospinal fluid (CSF) facilitates the early diagnosis of dementia in Alzheimer patients. More...


The biomarker, soluble circulating low-density lipoprotein receptor-related protein-1 (sLRP), provides key plasma binding activity for Alzheimer's disease (AD) amyloid-β peptide (Aβ).

Scientists at the University of Gothenburg (Gothenburg, Sweden) investigated the presence of sLRP in a total of 60 patients who were being investigated for dementia and took part in the study, along with 20 healthy controls. The study group included 14 patients with mild cognitive impairment (MCI) who progressed to AD (MCI-AD), 14 with AD, and 14 neurologically healthy controls. The investigators determined the amount of plasma oxidized sLRP and Aβ40/42 sLRP-bound, other proteins-bound and free plasma fractions, CSF tau/Aβ42 ratios, and mini-mental state examination (MMSE) scores in the study participants. The sLRP normally binds 70% - 90% of plasma Aβ preventing free Aβ access to the brain. In AD, Aβ binding to sLRP is compromised by increased levels of oxidized sLRP, which does not bind.

In MCI-AD patients prior to conversion to AD and AD patients, the increases in oxidized sLRP and free plasma Aβ40 and Aβ42 levels were 4.9 and 3.7-fold, 1.8, and 1.7-fold and 4.3 and 3.3-fold, respectively. In MCI-AD and AD patients, increases in oxidized sLRP and free plasma Aβ40 and Aβ42 correlated with increases in CSF tau/Aβ42 ratios and reductions in MMSE scores. The 24 patients who were considered as stable MCI patients were followed over a 2-4 years period had normal CSF tau/Aβ42 ratios, but increased oxidized sLRP levels.

The scientists concluded that these measurements could also be used to identify AD during the early stages of the disease. In such cases, the biomarkers can be used to identify those patients with mild symptoms who are most likely to benefit from treatment. The investigators also saw that patients who had not yet met all the clinical criteria for AD had similar levels of the biomarkers in their spinal fluid to patients who had developed the disease fully. The study was published in April 2011, in the Journal of Alzheimer's Disease.

Related Links:

University of Gothenburg




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.